Renal transplantation-related risk factors for the development of uterine adenomatoid tumors  by Mizutani, Teruyuki et al.
Gynecologic Oncology Reports 17 (2016) 96–98
Contents lists available at ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase seriesRenal transplantation-related risk factors for the development of uterine
adenomatoid tumorsTeruyuki Mizutani a,⁎, Osamu Yamamuro a, Noriko Kato a, Kazumasa Hayashi a, Junya Chaya a,
Norihiko Goto b, Toyonori Tsuzuki c
a Department of Obstetrics and Gynecology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
b Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan
c Department of Pathology, Nagoya Daini Red Cross Hospital, Nagoya, Japan⁎ Corresponding author at: Department of Obstetrics
Red Cross Hospital, 2-9 Myouken-chou, Shouwa-ku, Nago
E-mail address: teruyuki@nagoya2.jrc.or.jp (T. Mizuta
http://dx.doi.org/10.1016/j.gore.2016.05.003
2352-5789/© 2016 The Authors. Published by Elsevier Inca r t i c l e i n f o Red Cross Hospital during April 2003 through March 2011. All of theArticle history:
Received 16 December 2015
Received in revised form 29 April 2016
Accepted 8 May 2016
Available online 11 May 2016
Keywords:
removed specimen materials were diagnosed by a pathologist. The
epidemiologic and clinical manifestations of uterine ATs from
immunosuppressed renal transplant recipients were analyzed.
This work was reviewed and approved by the Institutional Review
Board of Nagoya Daini Red Cross Hospital. Informed consent was ob-
tained from all patients.
Data were analyzed using SPSS version 21.0 (IBM, Armonk, NY,Uterine
Benign tumors
Adenomatoid tumors
Renal transplantation
Immunosuppression
DialysisThere were 1094 total hysterectomies performed during the study1. Introduction
The term adenomatoid tumor (AT) was introduced by Golden and
Ash (Golden and Ash, 1945) to describe a tumor with distinct morpho-
logic features resembling an adenoma but having obscure histogenesis.
Currently, ATs are considered to be specialized benign mesothelial tu-
mors, (Ferenczy et al., 1972; Taxy et al., 1974) usually found in the gen-
ital systems of bothmales and females, and only rarely reported in other
sites such as the adrenal gland and peritoneum (Craig and Hart,
1979).With respect to uterine ATs, although three such ATs have been
reported as occurring in renal transplant recipients under immunosup-
pression therapy, (Bülent Tiras et al., 2000; Cheng andWee, 2003) there
has been no report suggesting that AT might occur frequently in renal
transplant recipients under immunosuppression therapy.
2. Materials and methods
We conducted a retrospective study of all patients who underwent
total hysterectomy (all types, such as simple total hysterectomy, modi-
ﬁed radical hysterectomy, and radical hysterectomy) at Nagoya Dainiand Gynecology, Nagoya Daini
ya, Aichi 466-8650, Japan.
ni).
. This is an open access article underUSA). Comparisons were assessed by the Fisher's exact test and the
Mann-Whitney U test. The level of signiﬁcance was selected at P b 0.05.
3. Results
period. Uterine ATs (Figs. 1 and 2) were found in 17 (1.55%) of the
1094 reviewed cases. Among the 17 patients (median age, 46 years;
age range, 24–73 years)with uterine ATs, 10 (58.8%)were immunosup-
pressed renal transplant recipients (Table 1). The other seven patients
had no special medical history. Of the 17 cases of uterine AT, irregular
menses was the main complaint in seven (41%), whereas three (18%)
patients had reported hypermenorrhea, two (12%) had suffered dys-
menorrhea, and two (12%) had asymptomatic swelling. Other patients
had urinary retention or no symptoms, and in one patient, the AT was
accidentally discovered via Porro's operation. Preoperatively, 12 pa-
tients were diagnosed with uterine leiomyomas, two with endometrial
cancer, onewith endometrial hyperplasia, onewith pseudoaneurysm of
the uterine artery, and one with ovarian cancer. None of the 1094 pa-
tients who underwent total hysterectomy were infected with human
immunodeﬁciency virus (HIV). Moreover, none of the patients were di-
agnosed preoperativelywith AT; all of the ATswere found in the hyster-
ectomy specimens after surgery. It was difﬁcult to investigate internal
medication use among all patients.
Of the 1094 hysterectomy patients, 14 (1.28%) were immunosup-
pressed renal transplant recipients. Of these 14 immunosuppressed
renal transplant recipients, 10 (71.4%) had uterine ATs, which were
found in the hysterectomy specimens after surgery. A signiﬁcant differ-
ence was observed between occurrence and non-occurrence of AT in
the renal transplant recipients (P b 0.001). The four renal transplant re-
cipients without uterine ATs had undergone hysterectomy for uterine
leiomyomas, cervical cancer, endometrial cancer, and hematometrathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Microscopic ﬁndings of adenomatoid tumor. Microscopically, the tumor is
composed of ramifying tubular, cystic spaces made by non-atypical mesothelial-like
cells between smooth muscle cells. These spaces are lined by cuboidal or ﬂattened cells.
Fig. 2. Immunostain of adenomatoid tumor. Tubular formations lined by ﬂattened cells are
immunopositive for calretinin.
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tween the patients. All of the patients who received renal transplants
had experienced onset of renal failure. In the 10 patients with AT, the
causes of their renal failure were chronic glomerulonephritis (four pa-
tients), IgA nephropathy (three patients), pregnancy complication
(one patient), membranoproliferative glomerulonephritis (one pa-
tient), and nephrotic syndrome (onepatient). The causes of renal failureTable 1
Characteristics of renal transplant recipients with adenomatoid tumor (AT).
Age at operation
(y)
Age at dialysis
(y)
Age at transplant
(y)
Obstetrical
status
Medicines Prese
symp
40 27 36a 27 Nulligravida Unknown Irreg
44 30 30 Parturition 1 PSL Cys MZ Hype
44 33 34 Nulligravida PSL Cys MMF Irreg
44 24 32 Nulligravida PSL Cys MZ Irreg
46 25 29 38b Parturition 2 PSL Cys Urina
24 8c 11 Nulligravida PSL TAC Dysm
58 28 34 Parturition 1 PSL Cys MZ Irreg
52 38 40 Nulligravida PSL TAC No sy
41 30 36 Nulligravida PSL Cys MMF Hype
47 33 35 Nulligravida PSL Cys MMF Irreg
PSL, prednisolone; Cys, cyclosporine; MZ, mizoribine; MMF, mycophenolate mofetil; TAC, tacro
a Renal function deteriorated after kidney transplantation, and patient received hemodialys
b Renal function deteriorated after kidney transplantation, and patient underwent transplan
c Peritoneal dialysis.in the four patients without AT were IgA nephropathy, nephrosclerosis,
thrombotic thrombocytopenic purpura, and unknown origin.
Themedian length of time each of the 14 renal transplant recipients
who had been undergoing dialysis and the median duration from
transplantation to hysterectomy. The 10 AT patients had received
maintenance dialysis ranging in vintage from 7 to 172months (median,
43 months) until undergoing kidney transplantation. Only one patient
underwent temporary peritoneal dialysis. The four renal transplant re-
cipients without AT had received hemodialysis ranging from 3 to
27 months (median vintage, 10.5 years). The occurrence of AT was sig-
niﬁcantly increased by the length of time on dialysis (P b 0.047).
In the 10 renal transplant recipients with AT, the duration between
their kidney transplant surgery and hysterectomy ranged from 67 to
284months (median, 142.5 months). In the four renal transplant recip-
ients without AT, the duration between their kidney transplant opera-
tion and hysterectomy ranged from 39 to 250 months (median,
62.5 months).4. Discussion
Adenomatoid tumors of the uterus are benign, rare lesions of the fe-
male genital tract. Their actual incidencemay be higher than the record-
ed incidence because they are not usually biopsied due to their
leiomyoma-like appearance and small size (Bülent Tiras et al., 2000).
The incidence of adenomatoid tumors in the uterus has been reported
as between 0.1% and 1% (Tiltman, 1980). Although some cases of AT
have been discovered preoperatively as large multicystic tumors, (De
Rosa et al., 1992; Nogales et al., 2002) AT is difﬁcult to discover preoper-
atively. In the present study, all cases of AT were incidental ﬁndings in
hysterectomy specimens. One patient (5.88%) had a large cystic tumor
(Fig. 3) with a diameter of 10 cm; the other 16 patients had small,
solid tumors.
The rate of AT in this study (1.55%) was higher than that in previous
studies (Tiltman, 1980). The reason could be that immunosuppressed
renal transplant recipients have a predisposition for AT. In the present
study, the rate of AT in the patients who were not immunosuppressed
renal transplant recipients (0.65%) was the same as that in previous
studies.
When we found that AT occurred frequently in renal transplant re-
cipients under immunosuppression therapy, the ﬁrst cause that came
tomindwas peritoneal dialysis. Themesothelium cells leak to the intra-
peritoneal spaces during peritoneal dialysis, (JSDT (The Japanese Socie-
ty for Dialysis Therapy), 2009) and it is suggested that AT is generated
from the mesothelium (Ferenczy et al., 1972; Taxy et al., 1974). We
therefore conjectured that the cause could be attributed to peritoneal
dialysis. However, among the patients of the present study, there wasnting
tom
Original disease Preoperative
diagnosis
ular menses Chronic glomerulonephritis Myoma
rmenorrhea Chronic glomerulonephritis Myoma
ular menses Membranoproliferative glomerulonephritis Myoma
ular menses Chronic glomerulonephritis Endometrial cancer
ry retention Pregnancy nephropathy Myoma
enorrhea Nephrotic syndrome Myoma
ular menses Chronic glomerulonephritis Endometrial hyperplasia
mptoms IgA nephropathy Myoma
rmenorrhea IgA nephropathy Myoma
ular menses IgA nephropathy Myoma
limus.
is again.
tation again.
Table 2
Characteristics of renal transplant recipients without adenomatoid tumor (AT).
Age at operation
(y)
Age at dialysis
(y)
Age at transplant
(y)
Obstetrical
status
Medicines Presenting
symptom
Primary renal condition Preoperative
diagnosis
46 25 25 Parturition 1 PSL Cys Hypermenorrhea Unknown Myoma
51 43 43 Nulligravida PSL Cys MMF No symptoms IgA nephropathy Cervical cancer
60 55 57 Parturition 2 PSL Cys MMF Irregular menses Nephrosclerosis Endometrial cancer
42 36 37 Nulligravida PSL TAC MMF Irregular menses Thrombotic thrombocytopenic purpura Hematometra
PSL, prednisolone; Cys, cyclosporine; MMF, mycophenolate mofetil; TAC, tacrolimus.
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dialysis.
A patient who receives hemodialysis is in a state of chronic inﬂam-
mation (Jofré et al., 2006). AT is frequently found with inﬂammation
via pathological diagnosis. Some authors have reported that AT may
have a posttraumatic or inﬂammatory origin; these investigators have
proposed to stress the reactive, rather than the neoplastic, character of
ATs (Nogales et al., 2002; Youngs and Taylor, 1967; Weiss and
Tavassoli, 1988; Ross et al., 1989). The present study showed that the
length of time on dialysis prior to renal transplantation is a risk factor
for the development of adenomatoid tumors of the uterus.
There are approximately 300,000 end-stage renal disease patients
who have received hemodialysis in Japan. Almost all patients receiving
hemodialysis arewaiting for a donor kidney. In our hospital, as a whole,
20% of cases, and 40% of recent cases, are performed as preemptive
transplantation, which is a high level in Japan. None of the preemptive
renal transplantation cases have supported the hypothesis that the
length of time on dialysis before transplantation causes an increase in
the incidence of AT.
There is a possibility that AT is a drug-induced disease caused by im-
munosuppressants. A recent report related AT to the immunosup-
pressed state in a patient with human immunodeﬁciency virus
(Phitayakorn et al., 2011). Livingston et al. suggested that the extensive
growth pattern of AT involving the entiremyometrium, aswell as its as-
sociation with a component resembling multicystic mesothelioma,
might reﬂect the patient's diminished ability to limit neoplastic process-
es (Bülent Tiras et al., 2000). It could be that the immunosuppressed
state might promote AT rather than the immunosuppressive drugs
themselves.Fig. 3. Magnetic resonance imaging (MRI) scan of cystic adenomatoid tumor. The T2-
weighted image revealed a 10.0-cm cystic tumor on the posterior wall of the uterus
showing high signal intensity.There are several limitations in this study. First, this study is retro-
spective design in single-centre site. Second, the number of admitted
patients with renal transplant recipient was small. Additionally, renal
transplanted patients have a better follow-up than other patients, lead-
ingmay be to higher hysterectomy rate and better data collection in this
group.
The present study showed that renal transplantation with immuno-
suppression therapy and length of time on dialysis are risk factors for
the development of adenomatoid tumors of the uterus. Further studies
are needed to explore these possibilities.
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